{"data":[{"vaccine_id":61,"vaccine_name":"Ebola virus recombinant adenovirus vector vaccine ADV−GP/NP","pathogen_id":13,"type":"Recombinant vector vaccine","description":"ADV−GP consists of an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) [Ref77:Sullivan et al., 2003].","status":"Research","vo_id":"VO_0004072"},{"vaccine_id":63,"vaccine_name":"GP","pathogen_id":13,"type":"Vaccinia virus (VACV)","description":"This vaccine comes from RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein [Ref86: Geisbert et al., 2002].","status":null,"vo_id":null},{"vaccine_id":64,"vaccine_name":"GP and NP","pathogen_id":13,"type":"DNA and adenovirus","description":"The vaccine components include nucleoprotein and three subtypes of Ebola glycoprotein, Zaire, Ivory Coast and Sudan (GP(Z,IC,S) + NP) [Ref79:Sullivan et al., 2000].","status":null,"vo_id":null},{"vaccine_id":65,"vaccine_name":"VRP expressing VP24","pathogen_id":13,"type":"VEEV replicon","description":"VP24 is an Ebola virus protein. It is membrane associated and is most likely located on the inside of the membrane. The function of VP24 is not known but it may serve as a minor matrix protein, facilitating the interaction of VP40 and/or GP with the RNP complex, or function in the uncoating of the virion during infection [Ref88:Wilson et al., 2001].","status":null,"vo_id":"VO_0000781"},{"vaccine_id":66,"vaccine_name":"VRP expressing VP30","pathogen_id":13,"type":"Recombinant vector vaccine","description":"VP30 is an Ebola virus protein. It associates with the genomic RNA in a ribonucleoprotein complex. The VP30 protein is not essential for replication, but it is necessary for efficient transcription in this system. It has also recently been shown to be essential for the recovery of infectious EBOV-Z from cloned cDNAs [Ref88:Wilson et al., 2001].","status":null,"vo_id":"VO_0000782"},{"vaccine_id":67,"vaccine_name":"VRP expressing VP35","pathogen_id":13,"type":"Recombinant vector vaccine","description":"VP35 is an Ebola virus protein. It associates with the genomic RNA in a ribonucleoprotein complex. It is essential for replication and encapsidation of the EBOV genome. The VP35 protein has also recently been shown to be essential for the recovery of infectious EBOV-Z from cloned cDNAs. In addition to being an essential component of the replication complex, VP35 was also recently implicated as an interferon antagonist. VP35 may therefore facilitate viral replication in infected cells by blocking the induction of antiviral immune responses normally induced by the production of interferon [Ref88:Wilson et al., 2001].","status":null,"vo_id":"VO_0000783"},{"vaccine_id":68,"vaccine_name":"VRP expressing VP40","pathogen_id":13,"type":"Recombinant vector vaccine","description":"VP40 is an Ebola virus protein.  It is membrane-associated and is most likely located on the inside of the membrane. VP40 has been shown to associate with cell membranes, where it is believed to be involved in maturation of the virus by inducing viral assembly at the plasma membrane of infected cells [Ref88:Wilson et al., 2001].","status":null,"vo_id":"VO_0000784"},{"vaccine_id":69,"vaccine_name":"GP-VRP","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":null,"vo_id":"VO_0000780"},{"vaccine_id":71,"vaccine_name":"GP and NP","pathogen_id":13,"type":"VEEV Replicon","description":"This immunogen is composed of RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein [Ref86:Geisbert et al., 2002].","status":null,"vo_id":"VO_0004073"},{"vaccine_id":72,"vaccine_name":"NP","pathogen_id":13,"type":"DNA","description":"NP (nucleoprotein) is a structural gene product of the Ebola virus [Ref103:Xu et al., 1998].","status":null,"vo_id":null},{"vaccine_id":73,"vaccine_name":"DNA vaccine expressing sGP","pathogen_id":13,"type":"DNA vaccine","description":"sGP is a secreted or transmembrane form of glycoprotein [Ref103:Xu et al., 1998].","status":null,"vo_id":"VO_0000785"},{"vaccine_id":443,"vaccine_name":"NP-VRP","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0011387"},{"vaccine_id":901,"vaccine_name":"Ebola virus DNA vaccine encoding ZEBOV GP and SEBOV GP","pathogen_id":13,"type":"DNA vaccine","description":null,"status":"Research","vo_id":"VO_0011465"},{"vaccine_id":3392,"vaccine_name":"Ebola virus DNA vaccine GP DNA","pathogen_id":13,"type":"DNA vaccine","description":null,"status":"Research","vo_id":"VO_0004334"},{"vaccine_id":3393,"vaccine_name":"Ebola virus recombinant rAD-GP encoding GP","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004335"},{"vaccine_id":3394,"vaccine_name":"Ebola virus recombinant VSVΔG-GP encoding GP","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004336"},{"vaccine_id":3395,"vaccine_name":"Ebola virus recombinant vector vaccine EBO7 encoding GP from SEBOV and ZEBOV","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004337"},{"vaccine_id":3574,"vaccine_name":"Ebola virus recombinant vector vaccine pVSVXN2∆G/ZEBOVsGP encoding GP","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004381"},{"vaccine_id":3575,"vaccine_name":"Ebola virus DNA vaccine EBODNA012-00-VP encoding GP","pathogen_id":13,"type":"DNA vaccine","description":null,"status":"Research","vo_id":null},{"vaccine_id":3576,"vaccine_name":"Ebola virus DNA vaccine EBOV GP","pathogen_id":13,"type":"DNA vaccine","description":null,"status":"Research","vo_id":"VO_0004036"},{"vaccine_id":3577,"vaccine_name":"Ebola virus EBOV NP","pathogen_id":13,"type":"DNA vaccine","description":null,"status":"Research","vo_id":"VO_0004037"},{"vaccine_id":3578,"vaccine_name":"Ebola virus DNA vaccine ADV–NP encoding NP","pathogen_id":13,"type":"DNA vaccine","description":"[Ref1075:Bukreyev et al., 2006][Ref1075:Bukreyev et al., 2006]","status":"Research","vo_id":null},{"vaccine_id":3579,"vaccine_name":"Ebola virus recombinant adenovirus vaccine AdC7-ZGP encoding GP","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004382"},{"vaccine_id":3580,"vaccine_name":"Ebola virus recombinant vector vaccine Ad-CMVZGP encoding the glycoprotein","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004383"},{"vaccine_id":3581,"vaccine_name":"Ebola virus recombinant vector vaccine Ad-CAGoptZGP encoding the envelope glycoprotein","pathogen_id":13,"type":"Recombinant vector vaccine","description":null,"status":"Research","vo_id":"VO_0004384"}],"meta":{"page":1,"per_page":25,"count":25,"total":54}}